Ongoing clinical trials are evaluating anti-TIGIT antibodies in melanoma patients, particularly those with high TIGIT expression, to determine their effectiveness in enhancing anti-tumor immune responses [37]. This evidence concerns the gene TIGIT and neoplasm.